IDH1 and glioma: In conclusion, this meta-analysis highlights that there are specific molecular (such as IDH1 mutations and 1p19q LOH) and pathological features and a better prognosis in CIMP-positive gliomas, suggesting that CIMP could be used as an independent prognostic marker for glioma.